1 top growth stock on my Christmas buy list!

Ben McPoland reveals one top-notch growth stock down 29% that he plans to stuff into his portfolio in time for Christmas dinner.

| More on:
Surprised Black girl holding teddy bear toy on Christmas

Image source: Getty Images

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

At first glance, Novo Nordisk (NYSE: NVO) might not look like a growth stock. After all, the Danish pharma giant is approaching its 101st birthday! Yet the figures speak for themselves.

Last year, revenue and operating profit grew 31% and 37%, respectively. This year, those figures are excepted to be 23% and 24%, which is impressive growth for any company.

The stock has surged 272% over five years. However, it’s down 29% since June, which I think has opened up an attractive long-term opportunity for my portfolio.

From insulin to weight loss

Novo Nordisk is a leader in diabetes care. It commands a 34% share of the $50bn+ global diabetes market, including nearly half of the insulin therapy market.

In 2018, the firm launched Ozempic for type 2 diabetes. This medication contains semaglutide, which mimics the gut-produced hormone GLP-1, crucial for regulating blood sugar levels and appetite.

In 2021, Novo introduced Wegovy as a specific injectable weight-loss treatment. It contains a higher-dose version of semaglutide and can help patients lose up to 16% of their body weight.

The company now dominates the booming global GLP-1 market, with a 65% patient volume share. Both Ozempic and Wegovy are blockbuster drugs, with the latter now approved in China for weight loss.

Potential wonder drug

Today, over 2.5bn people are classed as overweight or clinically obese. By the end of this decade, that could rise above 3bn.

Yet only a small fraction of these people are medically treated (around 2% for obesity), offering an enormous potential runway of growth. Meanwhile, diabetes rates continue to rise globally.

Remarkably, GLP-1 products could also benefit patients with chronic kidney disease, heart disease, alcohol addiction, arthritis, and perhaps even Alzheimer’s.

Some analysts see the obesity treatment market alone growing to around $170bn by the early 2030s!

Risks

Of course, this gigantic opportunity isn’t a secret, and lots of potential rivals are popping up with their own potential weight-loss candidates (including oral ones). So competition is a risk, especially from Eli Lilly, the maker of rival drug Zepbound (or Mounjaro in the UK).

New entrants may well drive down prices over the long term as they all vie for market share.

Plus, Novo is due to release data for its next-generation potential treatment (CagriSema). And its set a high bar, aiming for the drug to cut weight by 25% in just over a year. That would make it best-in-class.

If CagriSema results disappoint though, the stock could sell off, and vice versa. A lot is riding on it, particularly as the drugmaker faces the eventual loss of exclusivity on Ozempic and Wegovy.

I’m bullish

The reason I’m confident that Novo can maintain its market-leading position in the weight-loss sector is down to its massive investments in research and development (R&D).

The company is aggressively ramping up R&D spend to stay ahead of rivals, as we can see below.

Created at TradingView

Looking ahead to 2025, the firm is due to release data from a late-stage trial of semaglutide in early Alzheimer’s. That could be another massive potential market.

The stock’s trading at 27 times forward earnings, which isn’t cheap. But for an investor like myself with a long-term time horizon, I think it looks attractive. It’s top of my December buy list.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Ben McPoland has no position in any of the shares mentioned. The Motley Fool UK has recommended Novo Nordisk. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

A 7% dividend yield but down 16%! Is this mining giant a no-brainer?

This FTSE 100 mining titan has taken quite a tumble, but the dividend yield's now high, and long-term tailwinds might…

Read more »

Abstract bull climbing indicators on stock chart
Investing Articles

3 S&P 500 stocks that could surge under Donald Trump as US president

These three S&P 500 companies are all set to benefit from Trump’s planned policies, so they might be set to…

Read more »

Investing Articles

£5,000 invested in a FTSE 250 index fund during Covid would be worth this now

Zaven Boyrazian looks at the FTSE 250 index’s performance since the pandemic ravaged the world. Has an index fund been…

Read more »

Investing Articles

£5,000 invested in the FTSE 100 at the start of 2024 would be worth this now

The FTSE 100's up by double-digits, but it’s Britain’s banks that are stealing the show. Here’s how much profit investors…

Read more »

Man smiling and working on laptop
Investing Articles

2 high-yield dividend shares to consider for a BIG second income in 2025

Looking for ways to make a market-beating second income next year? You might want to take a look at these…

Read more »

Smiling diverse couple holding Christmas presents while walking through a winter forest
Investing Articles

2 FTSE 100 and FTSE 250 value stocks to consider in December!

Searching for the best FTSE 100 and FTSE 250 bargain shares? Here, Royston Wild picks out two of his favourites…

Read more »

Investing Articles

3 mega-cheap small-cap stocks to consider in December!

These small-cap stocks are on sale right now. Royston Wild thinks they merit serious attention, even from investors chasing passive…

Read more »

White female supervisor working at an oil rig
Growth Shares

Based on these oil price forecasts, the BP share price could have a tough 2025

Jon Smith explains why he thinks a stagnant oil price could be a problem for the BP share price over…

Read more »